Meeting
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
Authors
Eric Schafer
Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Eric Schafer , Rachel E. Rau , Xiaowei Liu , Charles G. Minard , David R. D'Adamo , Rachael Scott , Larisa Reyderman , Gresel Minette V. Martinez , Elizabeth Fox , Brenda Weigel , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT02171260
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2567)
DOI
10.1200/JCO.2016.34.15_suppl.2567
Abstract #
2567
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati
Poster
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
First Author: Sarah Leary
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).
First Author: Arif Manji